Teva Pharms Usa Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS USA, and what generic and branded alternatives to TEVA PHARMS USA drugs are available?
TEVA PHARMS USA has one hundred and ninety-six approved drugs.
There are twenty-nine tentative approvals on TEVA PHARMS USA drugs.
Summary for Teva Pharms Usa
| US Patents: | 0 |
| Tradenames: | 172 |
| Ingredients: | 169 |
| NDAs: | 196 |
Drugs and US Patents for Teva Pharms Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | AMLODIPINE AND OLMESARTAN MEDOXOMIL | amlodipine besylate; olmesartan medoxomil | TABLET;ORAL | 091154-001 | Oct 26, 2016 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Teva Pharms Usa Inc | FULVESTRANT | fulvestrant | SOLUTION;INTRAMUSCULAR | 210063-001 | Aug 19, 2019 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Teva Pharms Usa | ARFORMOTEROL TARTRATE | arformoterol tartrate | SOLUTION;INHALATION | 200293-001 | Nov 9, 2021 | AN | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Teva Pharms Usa | DULOXETINE HYDROCHLORIDE | duloxetine hydrochloride | CAPSULE, DELAYED REL PELLETS;ORAL | 090783-003 | Dec 11, 2013 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Teva Pharms Usa | CAPECITABINE | capecitabine | TABLET;ORAL | 091649-001 | Sep 16, 2013 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharms Usa
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,620,847 | ⤷ Sign Up |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 8,367,605 | ⤷ Sign Up |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 6,620,847 | ⤷ Sign Up |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 6,939,539 | ⤷ Sign Up |
| Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 6,342,476 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARMS USA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
| ➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
| ➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
| ➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
